StemSave Blog

In a phase 1 clinical trial, a novel mesenchymal stem cell [MSCs] therapy was successfully applied to treat often fatal steroid resistant graft versus host disease [GVHD]. A significant concern with life-saving organ and bone marrow transplants is the risk of immune rejection. GVHD occurs when the transplanted immune cells attack the patient’s body, with patients typically suffering from painful ulcers all over the body, and in extreme cases, death. The therapy, created by Cynata Therapeutics, is called CYP-001, and utilizes mesenchymal stem cells [the same type of cells found in teeth] to treat steroid resistant GVHD. This treatment gives hope to thousands of patients around the world receiving bone marrow transplants and risking the extremely fatal immune response.